Basit öğe kaydını göster

dc.contributor.authorTurkmenoglu, Fatma Pinar
dc.contributor.authorBaysal, İpek
dc.contributor.authorCiftci-Yabanoglu, Samiye
dc.contributor.authorYelekci, Kemal
dc.contributor.authorTemel, Hamdi
dc.contributor.authorPaşa, Salih
dc.contributor.authorEzer, Nurten
dc.contributor.authorÇalış, İhsan
dc.contributor.authorUcar, Gulberk
dc.date.accessioned2019-12-16T10:09:51Z
dc.date.available2019-12-16T10:09:51Z
dc.date.issued2015
dc.identifier.issn1420-3049
dc.identifier.urihttps://doi.org/10.3390/molecules20057454
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6272178/
dc.identifier.urihttp://hdl.handle.net/11655/19983
dc.description.abstractThe inhibitory effects of flavonoids on monoamine oxidases (MAOs) have attracted great interest since alterations in monoaminergic transmission are reported to be related to neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases and psychiatric disorders such as depression and anxiety, thus MAOs may be considered as targets for the treatment of these multi-factorial diseases. In the present study, four Sideritis flavonoids, xanthomicrol (1), isoscutellarein 7-O-[6'''-O-acetyl-β-d-allopyranosyl-(1→2)]-β-d-glucopyranoside (2), isoscutellarein 7-O-[6'''-O-acetyl-β-d-allopyranosyl-(1→2)]-6''-O-acetyl-β-d-glucopyranoside (3) and salvigenin (4) were docked computationally into the active site of the human monoamine oxidase isoforms (hMAO-A and hMAO-B) and were also investigated for their hMAO inhibitory potencies using recombinant hMAO isoenzymes. The flavonoids inhibited hMAO-A selectively and reversibly in a competitive mode. Salvigenin (4) was found to be the most potent hMAO-A inhibitor, while xanthomicrol (1) appeared as the most selective hMAO-A inhibitor. The computationally obtained results were in good agreement with the corresponding experimental values. In addition, the x-ray structure of xanthomicrol (1) has been shown. The current work warrants further preclinical studies to assess the potential of xanthomicrol (1) and salvigenin (4) as new selective and reversible hMAO-A inhibitors for the treatment of depression and anxiety.
dc.relation.isversionof10.3390/molecules20057454
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleFlavonoids From Sideritis Species: Human Monoamine Oxidase (Hmao) Inhibitory Activities, Molecular Docking Studies And Crystal Structure Of Xanthomicrol
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalMolecules
dc.contributor.departmentFarmasötik Botanik
dc.identifier.volume20
dc.identifier.issue5
dc.identifier.startpage7454
dc.identifier.endpage7473
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster